Drug intelligence / Profile preview

Cell Culture Derived Trivalent Influenza Vaccine

Development stage: Unknown
Lead developer: CSL
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Cell Culture Derived Trivalent Influenza Vaccine (cTIV) is an inactivated, subunit influenza vaccine produced using cell culture technology. It is designed to induce an immune response against three specific strains of the influenza virus, providing protection against influenza disease. This vaccine represents an alternative to traditional egg-derived influenza vaccines.

Other names: cell culture-derived, inactivated, subunit influenza vaccine

Beyond the preview

Go deeper on Cell Culture Derived Trivalent Influenza Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cell Culture Derived Trivalent Influenza Vaccine.

Explore the full profile